A recent study published in The Lancet Global Health highlights a troubling trend of substandard cancer drugs circulating in several African countries. Research conducted across Ethiopia, Kenya, Malawi, and Cameroon revealed that about 17% of the tested cancer medications lacked the correct active ingredients. This presents significant risks for patients, potentially allowing tumors to progress without effective treatment. Experts, including Lutz Heide, stress the gravity of the findings, aiming to address the root causes of these quality issues, which may stem from poor manufacturing and storage practices.
An alarming number of people across Africa may be taking cancer drugs that don't contain the vital ingredients needed to contain or reduce their disease.
Around 17% of the researched drugs were found to have incorrect active ingredient levels, with potentially dangerous implications for cancer patients.
Heide emphasized the importance of this study, stating it sheds light on a problem that has not been previously measured.
The investigation's senior researcher noted that factors leading to substandard quality could include manufacturing faults or poor storage conditions.
Collection
[
|
...
]